Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 162R |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Renal |
| Current Generation (* indicates number of generations grown in Castrate host) |
13 |
| Average PDX Generation Time (days +/- SEM) | 205 ± 8 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 162R |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 162R | CDH1 | -1.176 | 0.885 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | FANCA | -1.143 | 0.905 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | MGA | -1.109 | 0.927 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | USP28 | -0.990 | 1.007 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | ATM | -0.990 | 1.007 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | RB1 | -0.973 | 1.019 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | ZFHX3 | -0.921 | 1.057 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | KMT2C | -0.910 | 1.064 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | SETDB1 | 0.494 | 2.817 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | USP7 | 0.516 | 2.860 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | NCOR2 | 0.565 | 2.958 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | STAB2 | 0.601 | 3.033 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | MRE11A | 0.602 | 3.037 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | AKT3 | 0.652 | 3.143 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | KMT2C | 0.947 | 3.855 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | MYC | 0.957 | 3.884 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | KMT2C | 1.039 | 4.110 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | EZH2 | 1.039 | 4.110 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | BRAF | 1.039 | 4.110 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | MET | 1.039 | 4.110 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 162R | CCND1 | 1.744 | 6.702 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 162R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | 8 |
| Primary Gleason Score | 4 |
| Secondary Gleason Score | 4 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 4 |
| Tumour Grade | pT3aN0 |
| D'Amico Risk Classification | 7 |
| Tumour Volume (in cc) | 3.4 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 162 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 5.8 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 162R |
| Patient Age (binned in 5 year age groups) | 65-69 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 162R | SETBP1 | 392 | 0.48 | Missense variant | '4/6 | . | 26.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 162R | XIRP2 | 524 | 0.45 | Missense variant | '9/11 | 6.52E-05 | 28.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 162R | NCOR2 | 522 | 0.32 | Frameshift variant | '34/47 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 162R | FOXA1 | 396 | 0.31 | Inframe deletion | '2/2 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table